Personal information

No personal information available

Activities

Funding (2)

Maximizing Duration of First Response in Young Patients with Mantle Cell Lymphoma

2024-07-01 to 2027-06-30 | Grant
Lymphoma Research Foundation (New York, US)
GRANT_NUMBER:

1192280

Source: check_circle
ProposalCentral

Phase 2 Study of Glofitamab in Richter's Syndrome

2023-04-01 to 2025-10-31 | Grant
Lymphoma Research Foundation (New York, US)
GRANT_NUMBER:

1022532

Source: check_circle
ProposalCentral

Works (24)

Frontline management of mantle cell lymphoma

Blood
2025-02-13 | Journal article
Contributors: Christine E. Ryan; Philippe Armand; Ann S. LaCasce
Source: check_circle
Crossref

Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

HemaSphere
2025-01 | Journal article
Contributors: Christine E. Ryan; Yue Ren; Svitlana Tyekucheva; Jon E. Arnason; Adam M. Boruchov; Caron A. Jacobson; David C. Fisher; Hari Miskin; Peter Sportelli; Jennifer R. Brown et al.
Source: check_circle
Crossref

A 3-pronged attack on TP53-mutated MCL

Blood
2025-01-30 | Journal article
Contributors: Christine E. Ryan; Ann S. LaCasce
Source: check_circle
Crossref

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Journal of Clinical Oncology
2024-12-07 | Journal article
Contributors: Matthew S. Davids; Christine E. Ryan; Benjamin L. Lampson; Yue Ren; Svitlana Tyekucheva; Stacey M. Fernandes; Jennifer L. Crombie; Austin I. Kim; Matthew Weinstock; Josie Montegaard et al.
Source: check_circle
Crossref

Is rituximab retro in mantle cell lymphoma?

Blood
2024-07-18 | Journal article
Contributors: Christine E. Ryan; Jonathon B. Cohen
Source: check_circle
Crossref

Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement

British Journal of Haematology
2023-12 | Journal article
Contributors: Christine E. Ryan; Rebecca L. Zon; Robert Redd; David C. Fisher; Roni Shouval; Anita Kumar; Jennifer L. Crombie; Hossein Sadrzadeh; Austin I. Kim; Lakshmi Nayak et al.
Source: check_circle
Crossref

Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023

Seminars in Hematology
2023-11 | Journal article
Contributors: Christine E. Ryan; Caron A. Jacobson
Source: check_circle
Crossref

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

Journal of Clinical Investigation
2023-11-15 | Journal article
Contributors: Stephen Jun Fei Chong; Fen Zhu; Olga Dashevsky; Rin Mizuno; Jolin X.H. Lai; Liam Hackett; Christine E. Ryan; Mary C. Collins; J. Bryan Iorgulescu; Romain Guièze et al.
Source: check_circle
Crossref

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

Leukemia
2023-04 | Journal article
Contributors: Christine E. Ryan; Danielle M. Brander; Paul M. Barr; Svitlana Tyekucheva; Liam R. Hackett; Mary C. Collins; Stacey M. Fernandes; Yue Ren; Yinglu Zhou; Mikaela M. McDonough et al.
Source: check_circle
Crossref

MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Future Oncology
2022-10 | Journal article
Contributors: Christine E Ryan; Matthew S Davids; Richard Hermann; Mina Shahkarami; Juliana Biondo; Sarang Abhyankar; Hasan Alhasani; Jeff P Sharman; Anthony R Mato; Lindsey E Roeker
Source: check_circle
Crossref

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies.

Blood advances
2021-08-01 | Journal article
Source: Self-asserted source
Christine E. Ryan

Outcomes of COVID-19 in patients with CLL: a multicenter international experience.

Blood
2020-09-01 | Journal article
Source: Self-asserted source
Christine E. Ryan

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.

Blood advances
2020-04-01 | Journal article
Source: Self-asserted source
Christine E. Ryan

BCL-2 Inhibitors, Present and Future.

Cancer journal (Sudbury, Mass.)
2019-11-01 | Journal article
Source: Self-asserted source
Christine E. Ryan

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Blood
2016-11-01 | Journal article
Source: Self-asserted source
Christine E. Ryan

Large Morel-Lavallée lesion presenting as fungating mass with skin ulceration.

Journal of clinical orthopaedics and trauma
2016-06-20 | Journal article
Source: Self-asserted source
Christine E. Ryan

Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd

Biology of Blood and Marrow Transplantation
2016-03 | Journal article
Contributors: Bita Sahaf; Christine E. Ryan; Andrew Rezvani; Hideki Nakasone; Joanne Otani; Steven Coutre; Robert Lowsky; Robert Negrin; David B. Miklos
Source: Self-asserted source
Christine E. Ryan via Crossref Metadata Search

Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes.

Haematologica
2015-10-22 | Journal article
Source: Self-asserted source
Christine E. Ryan

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages

Proc Natl Acad Sci USA
2015-03 | Journal article
Contributors: James Scott McClellan; Christopher Dove; Andrew J. Gentles; Christine E. Ryan; Ravindra Majeti
Source: Self-asserted source
Christine E. Ryan via Crossref Metadata Search

Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

Blood
2015-03-12 | Journal article
Source: Self-asserted source
Christine E. Ryan
grade
Preferred source (of 2)‎

Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation

Biology of Blood and Marrow Transplantation
2015-02 | Journal article
Contributors: Christine E. Ryan; Aaron C. Logan; Andrew Rezvani; Manali Kamdar; Hideki Nakasone; Bita Sahaf; Joanne Otani; Katherine A. Kong; Mark Klinger; Malek Faham et al.
Source: Self-asserted source
Christine E. Ryan via Crossref Metadata Search

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

mAbs
2015-01-01 | Journal article
Source: Self-asserted source
Christine E. Ryan
grade
Preferred source (of 2)‎

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

Journal of Translational Medicine
2013 | Journal article
Contributors: Satiro N De Oliveira; Jiexin Wang; Christine Ryan; Sherie L Morrison; Donald B Kohn; Roger P Hollis
Source: Self-asserted source
Christine E. Ryan via Crossref Metadata Search

Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy

Human Gene Therapy
2013-10 | Journal article
Contributors: Satiro Nakamura De Oliveira; Christine Ryan; Francesca Giannoni; Cinnamon L. Hardee; Irena Tremcinska; Behrod Katebian; Jennifer Wherley; Arineh Sahaghian; Andy Tu; Tristan Grogan et al.
Source: Self-asserted source
Christine E. Ryan via Crossref Metadata Search